Jeong-Tae Ju
Directeur/Membre du Conseil chez KOREA UNITED PHARM INC.
Provenance du réseau au premier degré de Jeong-Tae Ju
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 11 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Jeong-Tae Ju via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| Chung-Ang University | College/University | Doctorate Degree Graduate Degree Graduate Degree Doctorate Degree | |
| Hankuk University of Foreign Studies | College/University | Undergraduate Degree | |
Kyung Hee University
 Kyung Hee University Other Consumer ServicesConsumer Services Kyung Hee University provides academic courses and grants academic degrees. It has udergraduate, graduate, international student, and international faculty programs. The firm also provides scholarships and operates Kyung Hee Medical Center, Kyung Hee University Hospital at Gangdong, and Kangnam Korean Hospital. The company was founded on February 15, 1949 and is headquartered in Seoul, South Korea. | College/University | Doctorate Degree | |
| United Douglas Pharm, Inc | Chief Executive Officer | ||
| Wonkwang University | College/University | Undergraduate Degree | |
| Yonsei University | College/University | Graduate Degree | |
| Kangwon National University | College/University | Doctorate Degree | |
| Daegu University | College/University | Undergraduate Degree | |
| Seoul National University | College/University | Corporate Officer/Principal | |
Pelemed Co., Ltd.
 Pelemed Co., Ltd. Pharmaceuticals: GenericHealth Technology Pelemed Co., Ltd. is a South Korean company based in Seoul that specializes in the development of innovative anticancer drugs. Pelemed's technology platform, PeLeSeLect & AHEDD, overcomes mutation-mediated drug resistance and enables precision drug design for kinase-targeted therapies. The company's pipeline includes several drugs in various stages of development for the treatment of different types of cancer. Pelemed has received funding from the IP Voucher Funded by MSS and has a scientific advisory board that includes experts from the ASAN Medical Center Bio Core Facility. The company was founded in 2019, and its CEOs are Yong-Chul Kim and Soo-Yeon Jang. | Pharmaceuticals: Generic | Director/Board Member |
Statistiques
Internationale
| Corée du Sud | 10 |
| Etats-Unis | 2 |
Sectorielle
| Consumer Services | 9 |
| Health Technology | 2 |
Opérationnelle
| Director/Board Member | 8 |
| Corporate Officer/Principal | 8 |
| Doctorate Degree | 4 |
| Chief Executive Officer | 3 |
| Undergraduate Degree | 3 |
Relations les plus connectées
| Insiders | |
|---|---|
| Duk-Young Kang | 4 |
| Gun-Wook Kang | 3 |
| Gui-Ja Kim | 2 |
| Jin-Ho Cho | 2 |
| Yong-Woo Cho | 2 |
| Won-Ho Kang | 2 |
| Hyung-Rae Kim | 2 |
| Won-Tae Jeong | 2 |
| Yeon-Woong Choi | 2 |
| In-Cheol Choi | 2 |
| Won-Il Kal | 1 |
- Bourse
- Insiders
- Jeong-Tae Ju
- Connexions Sociétés
